A court has ruled that Bayer Pharmaceutical’s patent on the birth control pill Yaz is invalid, allowing other companies to sell generic versions- despite the possible increased risk of blood clots associated with Yaz and Yasmin. Both Yaz and Yasmin have declined in sales, but the number of women using generic alternatives has increased.